At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,247 enrolled
Drug / intervention
TheraSpheredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Post Approval, Multiple Centre, Open-Label, Non-Interventional, Registry Study to Evaluate Effectiveness of TheraSphere® in Clinical Practice in France
In Brief
An observational study evaluating TheraSphere for Hepatocellular Carcinoma. Completed, enrolled 1,247 participants across 37 sites.
Detailed Summary
The purpose of this registry study is to gather effectiveness, QoL, safety and procedural information on TheraSphere® for the treatment of participants with Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma (iCC) and liver metastases for colon cancer (mCRC) in real world clinical practice settings in France.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHepatocellular Carcinoma
CountriesFrance
CollaboratorsBiocompatibles UK Ltd
Timeline
N/ACompletedFinished
20192020202120222023202420252026
Enrollment StartMar 2019
First PostedAug 2019
Primary CompletionDec 2024
TodayJul 2026
First PostedAug 28, 2019
Enrollment StartMar 13, 2019
Primary CompletionDec 31, 2024
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 6.8 years ago
Interventions
TheraSpheredevice
Participants will receive treatment with TheraSphere in accordance with Instructions for Use